FDA approved Celcuity’s cancer drug Revtorpyk, but trading signals undershot expectations as the product’s commercial launch timeline slipped into the end of the quarter. The approval was widely anticipated, yet execution details delayed immediate market impact for investors monitoring near-term uptake. For biotech stakeholders, the episode underscores how launch readiness—beyond regulatory clearance—can drive short-term performance. Celcuity’s experience will likely shape how the market interprets other approvals that face rollout timing constraints, especially when label expansion or payer negotiations extend beyond the approval date.